Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter | Latest News RSS feed

Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter - Latest News

Vanda v. West-Ward: This Time, Dosage Adjustment Claims are Patent Eligible Subject Matter

“Generic drug manufacturers accused of infringement should fully appreciate the subjective nature of a § 101 defense when evaluating their litigation risk.” The Federal Circuit’s decision in Vanda Pha... read more

Diagnosis: Ineligible

The particular claims at ... which are patent-eligible. See Vanda Pharm. Inc. v. West-Ward Pharm. Int’l Ltd., 887 F.3d 1117, 1133–36 (Fed. Cir. 2018) (holding that method of treatment by administering ... read more

Applicability of §101 Challenges in ANDA Pharmaceutical Litigation

By utilizing §101 motions less than 2 percent of the time, generics are not fully availing themselves of the Supreme Court’s decisions in 'Alice', 'Mayo', and 'Myriad'. read more

Looking for another news?

Avadel Pharmaceuticals plc (AVDL)

patents and proprietary rights associated with the Drug may not provide adequate protection; patents licensed to us under our license agreement with Serenity that cover the Drug are subject to litigat... read more

Federal Circuit Patent Updates - April 2018

Wallach, J. Affirming PTAB decision in inter partes reexamination that claims were unpatentable as anticipated or obvious. "Our precedent allows the USPTO to intervene to defend a PTAB decision when a ... read more

Interim Results

The study read-out is planned for 2018 with a planned submission in 2019 On 22 November the Group announced a further strengthening of its existing partnership with Hikma (through its wholly owned sub... read more

USPTO issues guidance on patent eligibility of method of treatment claims in light of Vanda Pharmaceuticals

On June 7, 2018, the USPTO issued new guidance to its examining corps in the form of a memorandum discussing the Federal Circuit’s April 13, 2018 decision in Vanda Pharmaceuticals Inc. v. West-Ward Ph... read more

Vanda on Rehearing: Will the Federal Circuit Defy SCOTUS?

Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd., 887 F ... What the majority suggests, but does not say, is that Mayo’s claims would be patent eligible if they added one more step of injecting the ... read more

Patent Eligibility Remains Uncertain, Even After Recent Efforts to Bring Clarity

Balancing that power, however, the courts in recent years have tried to reign in the scope of the patent right by limiting the scope of patent-eligible subject matter ... claim involved merely “conven... read more

Avadel Pharmaceuticals plc (AVDL)

On June 2, 2017, Avadel Pharmaceuticals plc (the "Company") furnished to the holders of its ... of shareholders which is scheduled to be held at 12:00 Noon (Irish Standard Time) on Wednesday, June 28, ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us